Short Interest in Oculis Holding AG (NASDAQ:OCS) Decreases By 14.1%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 25,000 shares, a drop of 14.1% from the February 13th total of 29,100 shares. Based on an average daily trading volume, of 71,300 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company's shares are sold short.

Analyst Upgrades and Downgrades

OCS has been the topic of a number of recent analyst reports. Chardan Capital reiterated a "buy" rating and issued a $28.00 target price on shares of Oculis in a research note on Thursday, March 13th. Robert W. Baird increased their target price on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th. Finally, HC Wainwright reduced their target price on Oculis from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th.

Oculis Trading Down 0.4 %

OCS stock traded down $0.07 during midday trading on Friday, reaching $19.57. The company's stock had a trading volume of 51,962 shares, compared to its average volume of 46,011. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The stock has a fifty day simple moving average of $20.95 and a two-hundred day simple moving average of $17.22. Oculis has a 1 year low of $10.55 and a 1 year high of $23.08. The firm has a market capitalization of $854.47 million, a price-to-earnings ratio of -10.14 and a beta of 0.01.

Remove Ads

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, equities research analysts predict that Oculis will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

Several institutional investors have recently made changes to their positions in OCS. abrdn plc increased its stake in shares of Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after buying an additional 188,871 shares during the period. Citadel Advisors LLC purchased a new position in shares of Oculis during the fourth quarter valued at $389,000. XTX Topco Ltd purchased a new position in shares of Oculis during the fourth quarter valued at $225,000. Bank of America Corp DE increased its stake in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after buying an additional 10,667 shares during the period. Finally, Bellevue Group AG purchased a new position in Oculis in the fourth quarter valued at about $170,000. Hedge funds and other institutional investors own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.